Page last updated: 2024-10-26

dipyridamole and T-Cell Lymphoma

dipyridamole has been researched along with T-Cell Lymphoma in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Roig, T1
Bermúdez, J1

Other Studies

1 other study available for dipyridamole and T-Cell Lymphoma

ArticleYear
Microcalorimetric evaluation of the effect of combined chemotherapeutic drugs.
    Biochimica et biophysica acta, 1995, Jun-09, Volume: 1244, Issue:2-3

    Topics: Antineoplastic Agents; Calorimetry; Cell Death; Dipyridamole; Drug Synergism; Humans; Kinetics; Lymp

1995